SMAD2 and neoplasm: In this study, inhibition of ALK5 by the kinase inhibitor LY2157299 disrupted Smad2/3 signaling (supposedly leading to tumor suppression) but not non-Smad signaling via the toll-like receptors (TLRs, contributing to tumor progression) (Mohamed et al., 2024).